The present study aimed at evaluating the efficacy of abatacept (ABA) compared to tocilizumab (TCZ), assumed as a gold standard biologic treatment in the management of patients with giant cell arteritis (GCA).
An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis
Rossi, DanielaFirst
;Cecchi, Irene;Sciascia, Savino;Naretto, Carla;Alpa, Mirella;Roccatello, Dario
Last
2021-01-01
Abstract
The present study aimed at evaluating the efficacy of abatacept (ABA) compared to tocilizumab (TCZ), assumed as a gold standard biologic treatment in the management of patients with giant cell arteritis (GCA).
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
article.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
991.64 kB
Formato
Adobe PDF
|
991.64 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
